Bio-Techne Expands Collaboration with Oxford Nanopore for Advancements in Genetic Testing

Bio-Techne Strengthens Genetic Testing Collaboration with Oxford Nanopore Technologies

Bio-Techne Corporation enhances its strategic partnership with Oxford Nanopore Technologies, broadening its commercial rights to develop a robust portfolio of genetic products. This expanded agreement, which extends their collaboration until 2032, solidifies Bio-Techne's commitment to revolutionizing the landscape of genetic testing. Following the successful launch of the AmplideX® Nanopore Carrier Plus Kit in March 2025, the two companies aim to streamline the development and commercialization of targeted enrichment sequencing kits. These kits will focus on the screening and diagnosis of heritable genetic disorders, a growing area of interest in the life sciences sector.

Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, highlights the importance of this collaboration, stating that it reflects their dedication to advancing genetic testing solutions. The partnership leverages Bio-Techne's extensive diagnostic expertise and Oxford Nanopore's innovative molecular sensing technology. Together, they aim to create solutions that simplify workflows in laboratories while providing deeper insights into genetic conditions. This collaboration could potentially transform genetic testing into a more efficient, accessible process for healthcare providers and patients alike.

The implications of this partnership go beyond immediate product offerings, as it lays a strong foundation for future innovations in genetic diagnostics. As the demand for effective diagnostic solutions continues to rise, Bio-Techne's strategic move underscores its commitment to enhancing genetic testing capabilities. With over $1.2 billion in net sales for the fiscal year 2025 and a workforce of around 3,100 employees worldwide, Bio-Techne is well-positioned to lead in this evolving field, promising significant advancements in understanding and diagnosing genetic disorders.

In addition to the collaboration, Bio-Techne encourages stakeholders to engage with the company through its website and social media channels to stay updated on its latest offerings and innovations. The partnership with Oxford Nanopore represents a strategic alignment that not only benefits both companies but also has the potential to significantly impact patient outcomes in genetic healthcare. As the biotechnology industry continues to advance, Bio-Techne remains at the forefront, committed to delivering cutting-edge solutions for improved diagnostics.